SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tutogen Medical, Inc. (OTCBB: TTGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: leigh aulper who started this subject10/18/2000 11:39:45 AM
From: leigh aulper   of 56
 
Tutogen Medical Receives FDA Approval for Xenograft Soft Tissue
CLIFTON, N.J.--(BUSINESS WIRE)--Oct. 18, 2000--Tutogen Medical Inc. (AMEX:TTG - news) today announced that it has received a 510(k) clearance to market a new product, Tutopatch®, for the indications of general and plastic surgery.

Specific indications include, but are not limited to vaginal and rectal prolapse, pelvic floor reconstruction and hernias; including inguinal and umbilical.

Tutopatch® is the first Xenograft tissue that will be offered by Tutogen in the U.S. This introduction follows the successful launch of Tutopatch® in Europe. The product is produced from bovine pericardium harvested from the Company's controlled bovine herd and is preserved using Tutogen's patented Tutoplast® Process, which virally inactivates and preserves the tissue.

Manfred Kruger, President and CEO of Tutogen made the following comment; ``Tutopatch will allow Tutogen to rapidly expand its market share by eliminating dependence on human tissue. This is another step in our drive to become a leader in the bio-implant industry.''

Tutogen Medical Inc. utilizes its patented Tutoplast®process of tissue preservation and viral inactivation, to manufacture bioimplants for neurosurgical, orthopedic, reconstructive and general surgical indications. The Company's Tutoplast®products are sold and distributed worldwide by the Mentor Corporation (NMS:MNTR), Sulzer Medica (NYSE:SM - news), IOP Inc. and through subsidiaries in the U.S. and Germany.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News